MBRX vs. CDIO, JATT, DARE, XCUR, NAII, RNXT, LGVN, LVTX, TENX, and CGTX
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Cardio Diagnostics (CDIO), JATT Acquisition (JATT), Daré Bioscience (DARE), Exicure (XCUR), Natural Alternatives International (NAII), RenovoRx (RNXT), Longeveron (LGVN), LAVA Therapeutics (LVTX), Tenax Therapeutics (TENX), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.
Moleculin Biotech vs.
Cardio Diagnostics (NASDAQ:CDIO) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Cardio Diagnostics presently has a consensus target price of $2.00, indicating a potential upside of 296.43%. Moleculin Biotech has a consensus target price of $24.00, indicating a potential upside of 1,775.00%. Given Moleculin Biotech's higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Cardio Diagnostics.
In the previous week, Moleculin Biotech had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Moleculin Biotech and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.00 equaled Moleculin Biotech'saverage media sentiment score.
Cardio Diagnostics has higher revenue and earnings than Moleculin Biotech.
Moleculin Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Moleculin Biotech's return on equity of -157.44% beat Cardio Diagnostics' return on equity.
Cardio Diagnostics has a beta of 3.6, indicating that its share price is 260% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 22.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 7.1% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Moleculin Biotech received 224 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 49.46% of users gave Moleculin Biotech an outperform vote.
Summary
Moleculin Biotech beats Cardio Diagnostics on 7 of the 13 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:MBRX) was last updated on 2/22/2025 by MarketBeat.com Staff
